Video

Dr. Gomella on the FDA Approval of Enzalutamide in Nonmetastatic CRPC

Author(s):

Leonard Gomella, MD

In Partnership With:

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer (CRPC).

Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Related Content
FDA
November 21st 2024

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

David Parkinson, MD, president, chief executive officer, ESSA
November 1st 2024

ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC

Neeraj Agarwal, MD, FASCO, Presidential Endowed Chair of Cancer Research, Huntsman Cancer Institute; professor, medicine, University of Utah
October 31st 2024

Novel Prostate Cancer Treatment Increases Overall Survival Rates for Late-Stage Prostate Cancer Patients